Osteoclast-expanded supercharged NK cells perform superior antitumour effector functions Christopher.Koski@bruker.com Osteoclast-expanded supercharged NK cells perform superior antitumour effector functions Read More »
CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors Christopher.Koski@bruker.com CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors Read More »
A novel CD3ε fusion receptor allows use of T-cell engagers on TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape Christopher.Koski@bruker.com A novel CD3ε fusion receptor allows use of T-cell engagers on TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape Read More »
Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells Christopher.Koski@bruker.com Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells Read More »
Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer Cells Christopher.Koski@bruker.com Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer Cells Read More »
Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles simplomarketing Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles Read More »
Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes Christopher.Koski@bruker.com Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes Read More »
Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy Christopher.Koski@bruker.com Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy Read More »
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma Christopher.Koski@bruker.com Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma Read More »
Interleukin-27-polarized HIV-resistant M2 macrophages are a novel subtype of macrophages that express distinct antiviral gene profiles in individual cells: implication for the antiviral effect via different mechanisms in the individual cell-dependent manner Christopher.Koski@bruker.com Interleukin-27-polarized HIV-resistant M2 macrophages are a novel subtype of macrophages that express distinct antiviral gene profiles in individual cells: implication for the antiviral effect via different mechanisms in the individual cell-dependent manner Read More »
